查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992138

核酸药物市场：2026-2032年全球市场预测（依药物类型、分子类型、给药途径、治疗领域及最终用户划分）

Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核酸药物市值将达到 377.6 亿美元，到 2026 年将成长至 427.7 亿美元，到 2032 年将达到 934.6 亿美元，复合年增长率为 13.82%。

主要市场统计数据
基准年 2025 377.6亿美元
预计年份：2026年 427.7亿美元
预测年份 2032 934.6亿美元
复合年增长率 (%) 13.82%

对核酸疗法的简明策略展望，反映了科学突破、监管成熟度和产业扩充性的融合。

核酸疗法已从一个小众研究领域发展成为现代药物研发的主流支柱，这得益于递送系统、化学修饰和监管核准的突破性进展。近期临床的成功和核准流程证明了曾经备受质疑的治疗方法的合理性，科学界也正逐渐倾向于采用mRNA、 RNA干扰和反义技术等可扩展的方法。这些进展重塑了研发人员选择标靶、进行患者分层和评估平台经济性的方式，从而加快了从药物发现到首次人体临床试验的週期。

技术平台化、监管澄清和供应链韧性如何重塑核酸疗法领域的竞争格局？

核酸疗法领域正经历着一场变革性的转变，这场转变重新定义了竞争优势和计画可行性。技术的成熟——尤其是在递送载体、脂质奈米颗粒化学和精确化学修饰方面的进步——已将许多先前难以攻克的标靶转化为切实可行的治疗机会。同时，平台思维也变得至关重要。各机构透过建构可重复使用的开发框架，缩短了研发週期，并降低了后续候选化合物的技术风险。这种平台化也正在改变投资模式，资本越来越倾向于那些拥有成熟转换路径的公司，而不是那些只有孤立治疗概念的公司。

该评估旨在评估关税趋势如何推动核酸疗法供应链的本地化、成本重新分配以及采购和製造方面的策略转变。

贸易政策的变化以及关税上调的前景可能会对核酸领域开发商和供应商的经济状况和产业计画产生累积影响。进口关税的提高将影响关键原材料的成本基础，例如修饰核苷酸、脂质组成、层析法树脂和专用一次性耗材。随着上游工程製程原料成本的上升，企业将面临重新分配预算、优先考虑具有更清晰价值提案的专案或加快供应链本地化以维持获利能力和进度确定性的压力。

将药物模式、分子类别、给药途径、治疗领域和最终用户行为与策略性研发和商业化选择联繫起来的详细细分见解。

細項分析揭示了不同治疗模式、分子类别、给药途径、治疗领域和最终用户群体的差异化趋势，每种模式都需要不同的策略。根据药物类型，研发人员必须权衡反义寡核苷酸、DNA/RNA适体、mRNA疗法、核苷类似物和RNA干扰疗法（RNA干扰疗法又可细分为微型RNA、短髮夹RNA和短干扰RNA）的固有技术需求。投资于强调模组化化学和递送方法的平台，可望涵盖该频谱内的多种亚型。根据分子类型，大分子和小分子需要不同的决策框架，这会影响生产复杂性、分析控制策略以及储存和物流。

美洲、欧洲、中东、非洲和亚太地区的优势和细微的监管差异如何决定创新、製造和商业化在哪些地区加速发展？

区域趋势决定着创新、生产和商业化动力集中的地区，这需要在全部区域以地域为导向的策略。在美洲，生物技术产业丛集密集、资本获取便利性以及监管柔软性等因素共同推动了早期创新蓬勃发展，并促进了伙伴关係与衍生企业的积极交易。高效的临床试验基础设施和病患招募机制支持快速概念验证（PoC）试验，同时，对国内生产的投资也日益受到重视，以应对供应链和关税风险。

决定哪些参与者能够加速发展、实现规模化并获得商业性价值的策略性企业原型和必要的伙伴关係要求。

竞争格局由垂直整合的研发公司、专业平台供应商、合约研发生产机构 (CDMO) 以及试剂和设备供应商共同构成，它们紧密结合，形成一个完整的生态系统。领先的研发公司凭藉平台可重复性、成熟的临床应用以及建立策略伙伴关係关係的能力脱颖而出，从而降低后期研发风险。提供递送系统、新型化学技术或先进分析技术的专业平台供应商，透过支援多个治疗项目并降低合作伙伴的技术不确定性，正获得显着的影响力。

为领导者提供极具影响力的建议，将技术进步转化为业务韧性、监管应对力和商业性可行性。

行业领导者应采取重点策略，将科学洞见与业务韧性和商业性清晰度相结合。首先，优先投资于能够实现适应症和治疗方法以外的重复利用的平台。此类平台可降低额外的研发风险，并加速下一代专案的推进。其次，提高供应链透明度，实现关键原料供应商多元化，并探索区域製造伙伴关係，以降低关税和物流风险。第三，从专案设计的早期阶段就整合监管和品质方面的专业知识，以简化对比测试、交付前测试和CMC（化学、生产和品管）流程安排。

采用透明且多方面的调查方法，结合专家访谈、技术文献、监管审查和情境分析，以检验关键发现。

本摘要的研究采用多方面方法，结合第一手资料和二手资料，以确保其可靠性和相关性。第一手资料包括对开发人员、生产专家和监管专家的结构化访谈，以及对近期同行评审文献和临床试验註册资讯的整合，重点关注核酸疗法。二手资料涵盖技术评论、专利趋势和已发布的监管指导文件，以反映品质、安全性和分析要求方面不断变化的预期。

结论强调，整合平台能力、监管前瞻性和供应链韧性是核酸疗法长期成功的关键。

核酸疗法是现代医学中一个强大且快速发展的支柱，其特点是技术创新、监管知识的累积和营运重点的不断变化。该领域独特地融合了科学机会和物流复杂性。成功不仅取决于生物学创新，还取决于生产品质、供应链韧性以及与监管机构和支付方流程的策略协调。整合平台能力、儘早与监管机构沟通并采用地理均衡的供应策略的相关人员，最有能力将科学潜力转化为商业性和临床成果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：核酸类药物市场（依药物类型划分）

  • 反义寡核苷酸
  • DNA/RNA适体
  • 基于mRNA的疗法
  • 核苷类似物
  • RNA干扰（RNAi）治疗药物
    • 微型RNA（miRNA）
    • 短髮夹RNA（shRNA）
    • 短干扰RNA（SiORNA）

第九章：依分子类型分類的核酸药物市场

  • 聚合物
  • 低分子

第十章：核酸药物市场：依给药途径划分

  • 吸入
  • 肌肉内部
  • 静脉
  • 口服
  • 皮下

第十一章：核酸药物市场：依治疗领域划分

  • 心血管疾病
  • 感染疾病
    • 细菌感染疾病
    • 霉菌感染疾病
    • 病毒感染疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌
  • 罕见疾病

第十二章：核酸药物市场：依最终用户划分

  • 学术和研究机构
  • 合约研究机构
  • 医院和诊所
  • 製药和生物技术公司

第十三章 核酸药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：核酸药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 核酸药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国核酸药物市场

第十七章：中国核酸药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beam Therapeutics Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences, Inc.
  • GSK PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics NV
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics PLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-CA7E340319CE

The Nucleic Acid-Based Drugs Market was valued at USD 37.76 billion in 2025 and is projected to grow to USD 42.77 billion in 2026, with a CAGR of 13.82%, reaching USD 93.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 37.76 billion
Estimated Year [2026] USD 42.77 billion
Forecast Year [2032] USD 93.46 billion
CAGR (%) 13.82%

A concise strategic orientation to nucleic acid therapeutics reflecting the convergence of scientific breakthroughs, regulatory maturation, and industrial scalability

Nucleic acid-based therapeutics have transitioned from niche research curiosities to a mainstream pillar of modern drug development, driven by breakthroughs in delivery systems, chemical modification, and regulatory acceptance. Recent clinical successes and authorization pathways have validated modalities that once faced skepticism, and the scientific community has coalesced around scalable approaches for mRNA, RNA interference, and antisense technologies. These advances have reshaped how developers approach target selection, patient stratification, and platform economics, enabling more agile cycles from discovery to first-in-human trials.

The industry now operates at the intersection of precision biology and industrial biotechnology. Improvements in synthesis, purification, and analytics have reduced historical barriers, while modular platform design has accelerated translational timelines. At the same time, regulatory authorities have matured their frameworks to address modality-specific safety and quality concerns, increasing predictability for developers. As a result, decision-makers must balance scientific opportunity with practical considerations such as manufacturing scalability, supply chain robustness, and global regulatory alignment.

This executive summary synthesizes core trends shaping the field and delivers insights that leaders can apply to R&D prioritization, partnership selection, and operational planning. The aim is to present a concise, evidence-based perspective that supports strategic choices across discovery, clinical development, and commercialization.

How technological platformization, regulatory clarity, and supply chain resilience are reshaping competitive dynamics across the nucleic acid therapeutics landscape

The landscape for nucleic acid therapies has undergone transformative shifts that redefine competitive advantage and program viability. Technological maturation-particularly in delivery vectors, lipid nanoparticle chemistries, and precise chemical modifications-has converted many previously intractable targets into realistic therapeutic opportunities. Concurrently, platform thinking has become central: organizations build reusable development frameworks that shorten timelines and reduce technical risk for subsequent candidates. This platformization has changed investment patterns, as capital increasingly favors entities with demonstrated translational pathways rather than one-off therapeutic concepts.

Regulatory evolution has been equally consequential. Agencies have issued clearer guidances on quality attributes, control strategies, and clinical endpoints specific to nucleic acid modalities. This greater clarity reduces regulatory uncertainty and supports parallel investments in manufacturing and analytic capabilities. At the same time, the ecosystem of contract development and manufacturing organizations has expanded and specialized, enabling smaller developers to access GMP production and advanced analytics without owning large capital footprints.

Geopolitical influences and supply chain considerations now play a larger role in project planning. Sourcing of raw materials, specialized reagents, and instrumentation is more strategic, and companies actively diversify suppliers and regionalize certain production steps to mitigate disruption risk. Together, these shifts emphasize adaptability, resilience, and the importance of integrating scientific, regulatory, and operational strategies early in program planning.

Assessing how tariff dynamics are driving supply chain regionalization, cost reallocation, and strategic shifts in sourcing and manufacturing for nucleic acid therapies

Trade policy changes and the prospect of elevated tariffs can have a cumulative impact on the economics and operational planning of developers and suppliers in the nucleic acid sector. Increased import duties affect the cost base for critical inputs such as modified nucleotides, lipid components, chromatography resins, and specialized single-use consumables. When upstream input costs rise, organizations face pressure to reallocate budgets, prioritize programs with clearer value propositions, or accelerate localization of supply chains to preserve margin and timeline certainty.

Beyond direct cost implications, tariffs can influence strategic behavior. Companies may respond by reconfiguring supply chains to reduce cross-border movements of high-value components, investing in domestic manufacturing capacity to avoid tariff exposure, or renegotiating supplier contracts to shift risk. These adjustments carry operational lead times and capital implications; decisions to insource or regionalize production require rigorous assessment of technical feasibility, regulatory implications, and long-term demand stability.

Tariff pressure also affects collaboration models and licensing negotiations. When manufacturing costs and timelines become less predictable, counterparties increasingly structure agreements with contingency clauses and staged milestones tied to supply stability. For organizations that depend on global networks for materials and services, proactive scenario planning is essential to maintain development momentum. Ultimately, the cumulative impact of tariffs is not solely economic; it reshapes strategic priorities, accelerates regional manufacturing initiatives, and heightens the value of supply chain visibility and contractual flexibility.

Deep segmentation insights connecting drug modality, molecule class, administration route, therapeutic focus, and end-user behaviors to strategic R&D and commercialization choices

Segmentation analysis reveals divergent dynamics across modalities, molecular classes, administration routes, therapeutic areas, and end users that require differentiated strategies. Based on drug type, developers must balance the unique technical demands of antisense oligonucleotides, DNA/RNA aptamers, mRNA-based therapeutics, nucleoside analogs, and RNA interference therapeutics, with RNA interference further subdivided into microRNA, short hairpin RNA, and short interfering RNA; platform investments that favor modular chemistry and delivery approaches can unlock multiple subtypes within this spectrum. Based on molecule type, decision frameworks differ for large molecules compared to small molecules, influencing manufacturing complexity, analytical control strategies, and storage logistics.

Route of administration is a critical determinant of formulation strategy and commercial positioning; inhalation, intramuscular, intravenous, oral, and subcutaneous routes each impose distinct delivery, stability, and patient adherence considerations that influence clinical design and manufacturing specifications. Therapeutic area segmentation highlights how scientific and commercial risk profiles vary: cardiovascular, infectious, metabolic, neurological, oncology, and rare diseases each present different biomarker needs, regulatory pathways, and patient populations, with infectious disease indication suites spanning bacterial, fungal, and viral infections and oncology distinguished by hematologic malignancies versus solid tumors. Based on end-user, utilization patterns and procurement models diverge between academic and research institutes, contract research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies, shaping demand for specialized services, analytic packages, and partnership models.

Collectively, these segmentation lenses enable tailored go-to-market and R&D strategies. Portfolio prioritization should align modality strengths with unmet clinical needs and operational readiness, while manufacturing and quality investments must be matched to anticipated administration routes and end-user requirements to minimize translational friction.

How regional strengths and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific determine where innovation, manufacturing, and commercialization accelerate

Regional dynamics are defining where innovation, production, and commercialization momentum concentrate, requiring geographically informed strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, a combination of dense biotech clusters, capital availability, and regulatory agility drives robust early-stage innovation and high transaction activity for partnerships and spinouts. Clinical trial infrastructures and patient recruitment efficiencies support rapid proof-of-concept studies, while domestic manufacturing investments are increasingly prioritized to manage supply chain exposure and tariff risk.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and specialized public-private initiatives support translational pipelines, yet developers must navigate heterogeneous national reimbursement frameworks and varied clinical trial ecosystems. European manufacturing capacity emphasizes quality and technical specialization, often in close collaboration with academic centers to translate platform science. In the Asia-Pacific region, rapid expansion of technical capabilities, competitive manufacturing costs, and growing clinical capacities create attractive conditions for scale-up and late-phase development. Regional regulatory agencies are progressively modernizing frameworks and expanding expedited pathways, and local demand for innovative therapies is rising alongside government investments in biotech infrastructure.

Successful players tailor engagement models by region, aligning partnerships, manufacturing footprints, and regulatory strategies with local strengths. Executing regional playbooks that account for clinical operations, supply chain logistics, and market access nuances will determine the speed and sustainability of commercial rollouts.

Strategic company archetypes and partnership imperatives that dictate which players will accelerate development, enable scalability, and capture commercial value

Competitive landscapes are shaped by a mix of vertically integrated developers, specialist platform providers, contract development and manufacturing organizations, and reagent and instrument suppliers that together form a dense ecosystem. Leading developers differentiate through platform repeatability, demonstrated clinical translation, and the ability to secure strategic partnerships that de-risk late-stage development. Specialist platform providers that offer delivery systems, novel chemistries, or advanced analytics gain outsized influence because they enable multiple therapeutic programs and reduce technical uncertainty for partners.

Contract development and manufacturing organizations remain pivotal, providing access to GMP production, scale-up expertise, and regulatory support-particularly for organizations that prefer asset-light models. Suppliers of critical raw materials and analytical instruments hold strategic importance; their quality, lead times, and geographic footprint directly influence program timelines. Additionally, service providers offering regulatory intelligence, clinical operations tailored to nucleic acid modalities, and market access consulting play an increasingly central role in shaping successful launch strategies.

For decision-makers evaluating partnerships or M&A, the most attractive targets combine strong technical differentiation, reproducible manufacturing processes, and embedded regulatory experience. Assessments should prioritize proven scalability, IP robustness, and the flexibility to support multiple modalities across therapeutic areas.

High-impact recommendations for leaders to convert technological advances into operational resilience, regulatory readiness, and commercial execution

Industry leaders should adopt targeted strategies that align scientific capability with operational resilience and commercial clarity. First, prioritize platform investments that enable reuse across indications and modalities; such platforms reduce marginal development risk and accelerate next-generation programs. Second, build supply chain visibility and diversify suppliers for critical inputs, while exploring regional manufacturing partnerships to mitigate tariff and logistic exposure. Third, integrate regulatory and quality expertise early in program design to streamline comparability, release testing, and CMC timelines.

In parallel, structure partnerships and commercial agreements to reflect supply and regulatory uncertainties, using milestone-based frameworks, shared-risk manufacturing arrangements, and flexible licensing terms. Invest in translational analytics and biomarker strategies to sharpen patient selection and strengthen value dossiers for payers. Operationally, expand capabilities in advanced analytics, process characterization, and digital quality systems to improve batch consistency and support regulatory confidence. Finally, cultivate a talent pipeline that blends molecular biology, process engineering, and regulatory science, ensuring that cross-functional teams can translate platform innovations into reliable clinical and commercial outputs.

Adopting these actions will help organizations convert scientific advances into durable, scalable programs while preserving optionality amid shifting policy and market conditions.

A transparent multi-method research methodology combining expert interviews, technical literature, regulatory reviews, and scenario analysis to validate key insights

The research underpinning this summary draws on a multi-method approach combining primary and secondary evidence to ensure robustness and relevance. Primary inputs included structured interviews with developers, manufacturing specialists, and regulatory experts, as well as synthesis of recent peer-reviewed literature and clinical trial registries focused on nucleic acid modalities. Secondary sources encompassed technological reviews, patent landscapes, and public regulatory guidance documents to map evolving expectations around quality, safety, and analytical requirements.

Analytic methods integrated thematic synthesis of expert interviews with comparative assessments of manufacturing pathways, supply chain configurations, and route-of-administration considerations. Scenario analysis was employed to evaluate the operational implications of trade policy shifts and supply disruptions, while cross-regional comparisons identified regulatory and infrastructure differentials that influence program timelines. Quality control procedures included source triangulation, expert validation of key inferences, and a transparency log documenting data provenance and methodological choices.

This mixed-methods approach balances depth and breadth, providing a defensible foundation for strategic recommendations and enabling targeted follow-up analyses tailored to specific programs or operational questions.

Concluding synthesis emphasizing that integrated platform capabilities, regulatory foresight, and supply chain resilience determine long-term success in nucleic acid therapeutics

Nucleic acid therapeutics represent a durable and rapidly evolving pillar of modern medicine, characterized by technological innovation, regulatory learning, and shifting operational priorities. The field presents a unique combination of scientific opportunity and logistical complexity: success depends not only on biological innovation but also on manufacturing quality, supply chain resilience, and strategic alignment with regulatory and payer pathways. Stakeholders that integrate platform capabilities, early regulatory engagement, and geographically aware supply strategies are best positioned to convert scientific promise into commercial and clinical impact.

Moving forward, organizations should treat platform development and operational readiness as co-equal strategic objectives. By doing so, they can retain the agility to pursue diverse indications while ensuring that late-stage requirements do not create bottlenecks. The ability to anticipate policy shifts, diversify supply channels, and craft flexible partnerships will determine which programs progress efficiently and which face avoidable delays. Ultimately, the most successful actors will be those that combine deep scientific expertise with disciplined execution across manufacturing, regulatory, and commercial domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid-Based Drugs Market, by Drug Type

  • 8.1. Antisense Oligonucleotides
  • 8.2. DNA/RNA Aptamers
  • 8.3. mRNA-Based Therapeutics
  • 8.4. Nucleoside Analogs
  • 8.5. RNA Interference (RNAi) Therapeutics
    • 8.5.1. MicroRNA (MiRNA)
    • 8.5.2. Short Hairpin RNA (ShRNA)
    • 8.5.3. Short Interfering RNA (SiRNA)

9. Nucleic Acid-Based Drugs Market, by Molecule Type

  • 9.1. Large Molecule
  • 9.2. Small Molecule

10. Nucleic Acid-Based Drugs Market, by Route of Administration

  • 10.1. Inhalation
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Nucleic Acid-Based Drugs Market, by Therapeutic Area

  • 11.1. Cardiovascular Diseases
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Viral Infections
  • 11.3. Metabolic Disorders
  • 11.4. Neurological Disorders
  • 11.5. Oncology
    • 11.5.1. Hematologic Malignancies
    • 11.5.2. Solid Tumors
  • 11.6. Rare Diseases

12. Nucleic Acid-Based Drugs Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Nucleic Acid-Based Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nucleic Acid-Based Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nucleic Acid-Based Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nucleic Acid-Based Drugs Market

17. China Nucleic Acid-Based Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alnylam Pharmaceuticals, Inc.
  • 18.6. Amgen Inc.
  • 18.7. Arcturus Therapeutics Holdings Inc.
  • 18.8. Arrowhead Pharmaceuticals, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Beam Therapeutics Inc.
  • 18.11. Biogen, Inc.
  • 18.12. BioMarin Pharmaceutical Inc.
  • 18.13. BioNTech SE
  • 18.14. Bluebird Bio, Inc.
  • 18.15. CRISPR Therapeutics AG
  • 18.16. CureVac N.V.
  • 18.17. Dynavax Technologies Corporation
  • 18.18. Editas Medicine, Inc.
  • 18.19. Eli Lilly and Company
  • 18.20. Evotec SE
  • 18.21. F. Hoffmann-La Roche Ltd.
  • 18.22. Generation Bio Co.
  • 18.23. Gilead Sciences, Inc.
  • 18.24. GSK PLC
  • 18.25. Intellia Therapeutics, Inc.
  • 18.26. Ionis Pharmaceuticals, Inc.
  • 18.27. Merck & Co., Inc.
  • 18.28. Moderna, Inc.
  • 18.29. Novartis AG
  • 18.30. Novo Nordisk A/S
  • 18.31. Orna Therapeutics, Inc.
  • 18.32. Pfizer Inc.
  • 18.33. ProQR Therapeutics N.V.
  • 18.34. Sangamo Therapeutics, Inc.
  • 18.35. Sanofi SA
  • 18.36. Sarepta Therapeutics, Inc.
  • 18.37. Silence Therapeutics PLC
  • 18.38. Stoke Therapeutics, Inc.
  • 18.39. Takeda Pharmaceutical Company Limited
  • 18.40. Vertex Pharmaceuticals Incorporated
  • 18.41. Voyager Therapeutics, Inc.
  • 18.42. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)